Abstract
p14/p16 and p15 gene expression was assessed by quantitative polymerase chain reaction in purified plasma cells (PC) from 52 patients with symptomatic multiple myeloma (MM) and seven with smoldering MM in order to clarify the impact of these genes on the proliferative activity of tumor cells and patients' outcome. p15 expression was lower in symptomatic MM than in smoldering SMM (-1.80 vs.1.51,p=0.026); similar results were observed for p14/p16. MM patients whose PC displayed high p15 and/or p14/p16 expression had a lower percentage of S-phase PC than the remaining cases (1.79%+/-1.35 vs. 3.04%+/-1.42, p=0.028), favorable prognostic factors and longer survival (100% vs. 49%at 2.5 years; p=0.007).
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Proliferation*
-
Cyclin-Dependent Kinase Inhibitor p15 / biosynthesis
-
Cyclin-Dependent Kinase Inhibitor p15 / genetics*
-
Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis
-
Cyclin-Dependent Kinase Inhibitor p16 / genetics*
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Middle Aged
-
Multiple Myeloma / genetics*
-
Multiple Myeloma / metabolism
-
Multiple Myeloma / pathology*
-
Prognosis
-
Tumor Suppressor Protein p14ARF / biosynthesis
-
Tumor Suppressor Protein p14ARF / genetics*
-
Up-Regulation / genetics*
Substances
-
Cyclin-Dependent Kinase Inhibitor p15
-
Cyclin-Dependent Kinase Inhibitor p16
-
Tumor Suppressor Protein p14ARF